Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million
GANX•Q2 net loss narrows as R&D spending declines
Gain Therapeutics posted a Q2 net loss of $4.68 million, or $0.11 per share, narrowing from $0.19 per share a year earlier.
- R&D expense fell 21.78% to $2.1 million.
- G&A expense rose 8.7% to $2.5 million.
- Cash and cash equivalents totaled $13.1 million at June 30, down from $20.8 million at Dec. 31.
Rexaceract program advances after FDA review
The FDA completed its review of the IND for rexaceract, clearing the way for a Phase 2 start in Q3 2026.
Final Phase 1b results are expected in Q4.
